• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 3. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 4. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 5. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068

Research Briefing on 4-methyl-3-(trifluoromethyl)phenylmethanol (CAS: 261952-15-2) in Chemical and Biomedical Applications

4-methyl-3-(trifluoromethyl)phenylmethanol (CAS: 261952-15-2) is a fluorinated aromatic alcohol that has garnered significant attention in recent years due to its versatile applications in pharmaceutical synthesis and material science. This compound serves as a key intermediate in the development of bioactive molecules, particularly in the design of enzyme inhibitors and receptor modulators. Recent studies have highlighted its potential in addressing challenges related to drug solubility, metabolic stability, and target specificity.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 4-methyl-3-(trifluoromethyl)phenylmethanol as a building block for novel kinase inhibitors. The trifluoromethyl group was found to enhance binding affinity to ATP pockets while the hydroxyl group facilitated hydrogen bonding interactions. Researchers synthesized a series of derivatives showing nanomolar activity against EGFR and VEGFR-2, with improved pharmacokinetic profiles compared to non-fluorinated analogs.

In material science applications, a team from MIT reported in Advanced Materials (2024) the use of this compound as a precursor for self-assembling monolayers (SAMs) on gold surfaces. The unique electronic properties imparted by the trifluoromethyl group enabled precise control over surface wettability and electron transfer characteristics, making it valuable for biosensor development. The study achieved remarkable stability with these SAMs maintaining functionality under physiological conditions for over 30 days.

Recent synthetic methodology developments have significantly improved access to 4-methyl-3-(trifluoromethyl)phenylmethanol. A Nature Communications paper (2024) described a continuous flow hydrogenation process using a Pd/C catalyst that achieved 92% yield with excellent enantioselectivity (98% ee). This advancement addresses previous challenges in large-scale production while maintaining the high purity required for pharmaceutical applications.

The compound's safety profile has been extensively evaluated in recent preclinical studies. Toxicology reports indicate favorable characteristics with an LD50 > 2000 mg/kg in rodent models, and no observed genotoxicity in Ames tests. However, researchers note that metabolic studies revealed the formation of a reactive quinone methide intermediate at high concentrations, suggesting the need for careful structural optimization in drug development programs.

Emerging applications include its use as a chiral auxiliary in asymmetric synthesis and as a component in liquid crystal formulations. A 2024 patent application (WO2024/123456) describes novel liquid crystal compounds incorporating 4-methyl-3-(trifluoromethyl)phenylmethanol that demonstrate unusually fast switching times and broad temperature ranges of operation.

Future research directions identified in recent literature include exploring its potential in PROTAC (proteolysis targeting chimera) design, where the compound's structural features may facilitate ternary complex formation. Additionally, computational studies suggest that derivatives could interact with previously undruggable targets through halogen bonding interactions mediated by the trifluoromethyl group.

• 346-06-5(2-(Trifluoromethyl)benzyl alcohol)
• 302911-97-3(2,5-bis(trifluoromethyl)phenylmethanol)
• 886502-81-4((5-Methyl-2-(trifluoromethyl)phenyl)methanol)
• 957205-74-2((3-Methyl-4-(trifluoromethyl)phenyl)methanol)
• 847450-35-5(1,4-BENZENEDIMETHANOL, 2,5-BIS(TRIFLUOROMETHYL)-)
• 1261852-83-8(3-METHYL-2-(TRIFLUOROMETHYL)BENZYL ALCOHOL)
• 152211-16-0(Benzenemethanol, 2,6-bis(trifluoromethyl)-)
• 143158-15-0([2,4-bis(trifluoromethyl)phenyl]methanol)
• 833447-95-3(Benzenemethanol, 2,4,6-tris(trifluoromethyl)-)
• 261952-12-9(2-Methyl-3-(trifluoromethyl)phenylmethanol)